News

Parexel moves to pick up laid-off GlaxoSmithKline workers

Parexel is leasing a North Carolina building from GlaxoSmithKline, part of a deal between the two in which the CRO will absorb some researchers on the way out as the drugmaker mounts a major restructuring.

Australian CRO Novotech firms up its Hong Kong presence

Australia's Novotech has made a permanent home in Hong Kong, ditching its old office in favor of a larger space as it works to capitalize on the growing demand for clinical services in the region.

Trial tech outfit goBalto bags $12M to expand around the world

San Francisco's goBalto raised $12 million to push its clinical trial software, designed to expedite study startup.

EMA wants more than 700 drugs suspended over GVK data scandal

The European Medicines Agency is recommending its member states stop selling drugs tied to improprieties at a GVK Biosciences facility in India.

PPD beefs up its Irish outpost with a new biologics lab

PPD has amped up the biologics capabilities at its Irish manufacturing operation, opening a new lab devoted to the development of large-molecule treatments.

Covance pools its early-stage R&D services into one offering

Drug developers commonly deal with a host of CROs as they work their way from preclinical testing to first-in-human trials, a process designed to maximize the strengths of each contractor. But a piecemeal approach to early-stage development can lead to costly delays, according to Covance, which is pitching an all-encompassing offering it claims can seamlessly shuttle molecules from animal studies to Phase II.

Cel-Sci's $50M inVentiv suit heads to trial

Cel-Sci, seeking $50 million from former partner inVentiv Health, will soon get its day in court against the CRO.

Ergomed posts a big year with more in store for 2015

U.K. CRO Ergomed, which often shares the risks and rewards of R&D with its clients, grew its revenue by 14% in 2014, and the company hopes to ride a late-year boom into 2015.

AMRI inks a 10-year NIH deal with $37M on the line

In-transition drug developer AMRI has won a 10-year contract with the National Institutes of Health to help develop and manufacture neurological drugs.

Evotec strikes an R&D deal focused on addiction

The R&D innovators at Evotec have signed a deal to lend their drug discovery muscle to U.K. biotech C4X Discovery, hoping to develop selective drugs that can combat addiction without druggy side effects.

Sanofi taps Catalent for antibody R&D

Catalent has signed a collaboration deal with pharma giant Sanofi, lending out its proprietary approach to crafting antibody-guided treatments.

Clinipace banks $50M to scout for more deals

CRO Clinipace, which has pulled the trigger on 5 acquisitions in as many years, raised $50 million in debt and equity to bankroll the next phase of its expansion effort.

Novartis adds Qualcomm to its list of trial partners

Novartis, in the midst of a long-running effort to make clinical trials more efficient, has recruited Qualcomm to help it gather and store patient data from medical devices.

Quintiles' Novella partners up for cardio device R&D

Novella Clinical, owned by Quintiles, struck a deal with the Cardiovascular Research Foundation to join forces on trial services, expanding their existing relationship to create a seamless offering for medical device developers.

Evotec extends a biotech deal with $13M on the line

Evotec, a risk-sharing R&D collaborator, has extended its relationship with biotech startup Padlock Therapeutics, inking a new deal that will see the pair progress into preclinical development.

PPD's in-house biotech pairs up with J&J

X-Chem, a subsidiary of PPD, has signed a deal with Johnson & Johnson to provide its library of molecules to aid in the discovery of new treatments for inflammatory disease.

AMRI spends $60M to beef up its manufacturing heft

AMRI, on the mend after a rough quarter, is laying out $60 million to expand its manufacturing footprint, agreeing to buy a couple of outposts from service provider Aptuit.

WuXi buys big into genomics with NextCODE deal

Chinese CRO giant WuXi PharmaTech is continuing its push into genomic sequencing, paying $65 million for NextCODE Health, a Big Data-focused spinout of the high-profile deCODE.

Fujifilm deepens its CMO heft with Kalon buyout

Fujifilm has completed its acquisition of Kalon Biotherapeutics, a contract manufacturer with a focus on vaccines.

Evotec teams up with Ohio State on a new cancer drug

German contract researcher Evotec has paired off with Ohio State to help the school develop an in-house cancer prospect, lending its technology and expertise.